182 related articles for article (PubMed ID: 19147089)
41. Acute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative Neoplasms.
Czader M; Orazi A
Am J Clin Pathol; 2015 Aug; 144(2):188-206. PubMed ID: 26185305
[TBL] [Abstract][Full Text] [Related]
42. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
43. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.
Barbui T; Thiele J; Gisslinger H; Kvasnicka HM; Vannucchi AM; Guglielmelli P; Orazi A; Tefferi A
Blood Cancer J; 2018 Feb; 8(2):15. PubMed ID: 29426921
[TBL] [Abstract][Full Text] [Related]
44. Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders.
Kaushansky K
Cytokine Growth Factor Rev; 2006 Dec; 17(6):423-30. PubMed ID: 17055768
[TBL] [Abstract][Full Text] [Related]
45. Expression of c-Mpl and c-Mpl ligand gene in hematopoietic cells of individuals with and without myeloproliferative disorders and leukemia cell lines.
Sasaki A; Katoh O; Kawaishi K; Hyodo H; Kimura A; Satow Y; Kuramoto A
Int J Hematol; 1995 Dec; 62(4):217-23. PubMed ID: 8589367
[TBL] [Abstract][Full Text] [Related]
46. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).
Barosi G; Tefferi A; Besses C; Birgegard G; Cervantes F; Finazzi G; Gisslinger H; Griesshammer M; Harrison C; Hehlmann R; Hermouet S; Kiladjian JJ; Kröger N; Mesa R; Mc Mullin MF; Pardanani A; Passamonti F; Samuelsson J; Vannucchi AM; Reiter A; Silver RT; Verstovsek S; Tognoni G; Barbui T
Leukemia; 2015 Jan; 29(1):20-6. PubMed ID: 25151955
[TBL] [Abstract][Full Text] [Related]
47. Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders.
Reiter A; Walz C; Cross NC
Curr Drug Targets; 2007 Feb; 8(2):205-16. PubMed ID: 17305499
[TBL] [Abstract][Full Text] [Related]
48. Myeloproliferative Neoplasms: Diseases Mediated by Chronic Activation of Signal Transducer and Activator of Transcription (STAT) Proteins.
Liongue C; Ward AC
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254802
[TBL] [Abstract][Full Text] [Related]
49. Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian Mpn Group.
Busque L; Porwit A; Day R; Olney HJ; Leber B; Éthier V; Sirhan S; Foltz L; Prchal J; Kamel-Reid S; Karsan A; Gupta V
Am J Clin Pathol; 2016 Oct; 146(4):408-22. PubMed ID: 27686169
[TBL] [Abstract][Full Text] [Related]
50. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.
Mughal TI; Barbui T; Abdel-Wahab O; Kralovics R; Jamieson C; Kvasnicka HM; Mullaly A; Rampal R; Mesa R; Kiladjian JJ; Deininger M; Prchal J; Hehlmann R; Saglio G; Van Etten RA
Leuk Lymphoma; 2015 Jul; 56(7):1938-48. PubMed ID: 25330439
[TBL] [Abstract][Full Text] [Related]
51. Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.
Pandey R; Kapur R
Mol Cancer; 2015 Jun; 14():118. PubMed ID: 26062813
[TBL] [Abstract][Full Text] [Related]
52. A fifteen-year cytogenetic remission following interferon treatment in a patient with an indolent ETV6-ABL positive myeloproliferative syndrome.
Mozziconacci MJ; Sainty D; Chabannon C
Am J Hematol; 2007 Jul; 82(7):688-9. PubMed ID: 17366548
[No Abstract] [Full Text] [Related]
53. Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder.
Chatterjee A; Ghosh J; Kapur R
Oncotarget; 2015 Jul; 6(21):18250-64. PubMed ID: 26158763
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapy for myeloproliferative neoplasms (MPN).
Hofmann S; Babiak A; Greiner J
Curr Cancer Drug Targets; 2011 Jan; 11(1):72-84. PubMed ID: 21062247
[TBL] [Abstract][Full Text] [Related]
55. [Clinical aspects of myeloproliferative disorders excluding CML].
Komatsu N
Rinsho Ketsueki; 2008 Oct; 49(10):1411-9. PubMed ID: 18833926
[No Abstract] [Full Text] [Related]
56. Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.
Vannucchi AM; Guglielmelli P; Rambaldi A; Bogani C; Barbui T
J Cell Mol Med; 2009 Aug; 13(8A):1437-50. PubMed ID: 19522842
[TBL] [Abstract][Full Text] [Related]
57. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map.
Shallis RM; Wang R; Davidoff A; Ma X; Podoltsev NA; Zeidan AM
Blood Rev; 2020 Jul; 42():100706. PubMed ID: 32517877
[TBL] [Abstract][Full Text] [Related]
58. World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants.
Vardiman J; Hyjek E
Hematology Am Soc Hematol Educ Program; 2011; 2011():250-6. PubMed ID: 22160042
[TBL] [Abstract][Full Text] [Related]
59. Interferon-alpha in the treatment of myeloproliferative diseases.
Kissová J
Vnitr Lek; 2019; 65(11):699-703. PubMed ID: 31906676
[TBL] [Abstract][Full Text] [Related]
60. Myeloid neoplasms in the guise of nutritional deficiency.
Parthasarathy V
Case Rep Hematol; 2012; 2012():826939. PubMed ID: 23227377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
